Biology

Alpha-synuclein as a therapeutic target for Parkinson’s disease 2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Searching for therapeutic targets for Parkinson’s disease 1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease 1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Future prospects in Parkinson’s disease 1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Questioning the Braak hypothesis in Parkinson’s disease 3:42
Questioning the Braak hypothesis in Parkinson’s disease
Alberto Espay • 9 Sep 2021
Is clearing α-synuclein enough to treat Parkinson’s disease? 2:49
Is clearing α-synuclein enough to treat Parkinson’s disease?
Alberto Espay • 9 Sep 2021
How can we develop better DMTs in Huntington’s disease? 1:25
How can we develop better DMTs in Huntington’s disease?
Anne Rosser • 23 Sep 2021
Higher repair capability in early-onset vs late-onset pediatric multiple sclerosis 2:18
Higher repair capability in early-onset vs late-onset pediatric multiple sclerosis
Ermelinda De Meo • 27 Oct 2021
Autoreactive T-cell responses in multiple sclerosis: unanswered questions 2:14
Autoreactive T-cell responses in multiple sclerosis: unanswered questions
Olivia Thomas • 21 Oct 2021
The protective role of BDNF Val66Met against hippocampal atrophy and cognitive impairment in MS 3:18
The protective role of BDNF Val66Met against hippocampal atrophy and cognitive impairment in MS
Ermelinda De Meo • 27 Oct 2021
Recent evidence for subclinical disease activity in NMOSD 6:38
Recent evidence for subclinical disease activity in NMOSD
Bruce Cree • 21 Oct 2021
Similarities between the gut microbiome in Parkinson’s disease & MS 0:46
Similarities between the gut microbiome in Parkinson’s disease & MS
Paul Wilmes • 5 Oct 2021
Correlation between brain lesions and cognitive impairment 2:58
Correlation between brain lesions and cognitive impairment
Didier Leys • 11 Oct 2021
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD 5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
Targeting vascular risk factors to postpone cognitive impairment 3:18
Targeting vascular risk factors to postpone cognitive impairment
Didier Leys • 11 Oct 2021
Analysis of neurotransmitter metabolites in CSF in Parkinson’s Disease 1:19
Analysis of neurotransmitter metabolites in CSF in Parkinson’s Disease
Brit Mollenhauer • 24 Sep 2021
The content of VJNeurology is intended for healthcare professionals